The Latest Breaking News from Obesity

Excess weight, especially around the waist, leads to fatty material building up in the arteries and major organs

Preteens who own smartphones are likelier to have depression, obesity and insufficient sleep than their peers.

Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain.

Social isolation kills. It increases your risk of death by 30% — roughly the same as smoking cigarettes and much worse than factors such as obesity and sedentary living.

Some recent national numbers suggest the obesity rate has plateaued or even declined. Experts are skeptical.

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars.

About 2.5million people in the UK use GLP-1 drugs for weight loss

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

It is expected that the tablet will be much cheaper than weight loss jabs.

French regulators have intensified their crackdown on the booming online trade in illicit weight-loss medicines, targeting platforms and sellers pushing unlicensed anti-obesity products.